Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha? (Q39476778)

12 September 2017

title

Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha? (English)

1 reference

12 September 2017

1 reference

1 reference

H Sevim

1

1 reference

12 September 2017

J F Parkinson

series ordinal

2

1 reference

12 September 2017

K L McDonald

series ordinal

3

1 reference

12 September 2017

publication date

9 September 2011

1 reference

Journal of Cancer Research and Clinical Oncology

12 September 2017

published in

1 reference

12 September 2017

volume

137

1 reference

12 September 2017

issue

11

1 reference

12 September 2017

page(s)

1705-1712

1 reference

Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Penetration of etoposide into human malignant brain tumors after intravenous and oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Absence of major defects in non-homologous DNA end joining in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: A clinical study conducted at the Northern Israel Oncology Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Rechallenge with temozolomide in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1046-5

Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.

21 January 2018

1 reference

12 December 2020

NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIα and DNA-dependent protein kinase

1 reference

12 December 2020

Effects of thiols on topoisomerase-II alpha activity and cell cycle progression

1 reference

12 December 2020

26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.

1 reference

12 December 2020

Bid can mediate a pro-apoptotic response to etoposide and ionizing radiation without cleavage in its unstructured loop and in the absence of p53

1 reference

12 December 2020

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

1 reference

12 December 2020

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

1 reference

12 December 2020

DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer

1 reference

12 December 2020

Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis

1 reference

12 December 2020

Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression

1 reference

12 December 2020

10.1007/S00432-011-1046-5

Identifiers

DOI

1 reference

12 September 2017

1 reference